IPP Bureau
Orchid Pharma launches Rs. 500 Cr QIP programme
By IPP Bureau - December 02, 2022
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Alembic receives USFDA final approval for Diclofenac Sodium Topical Solution USP
By IPP Bureau - December 02, 2022
Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of US $512 million for twelve months ending Sep 2022 according to IQVIA
Zydus receives final approval from USFDA for Topiramate Extended-Release capsules
By IPP Bureau - December 02, 2022
Topiramate Extended-Release capsule had annual sales of US $68.8 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022)
Briefs: Piramal Enterprises and Shilpa Medicare
By IPP Bureau - December 02, 2022
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
Freudenberg Medical launches HelixFlex TPE Tubing for India
By IPP Bureau - December 01, 2022
TPE tubing is ideal for pharmaceutical bioprocessing applications because it can be welded to existing tubing lines, and heat-sealed to allow for easy, fast, and safe fluid transport in biopharma processes
SRL Diagnostics launches laboratory in Shimla
By IPP Bureau - December 01, 2022
The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
WuXi STA launches parenteral formulation manufacturing line at Wuxi
By IPP Bureau - December 01, 2022
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets
By IPP Bureau - December 01, 2022
This product is based on Osmotic Controlled Release Oral Delivery System technology
Botanical Solution and Croda Pharma inks agreement to accelerate production for GMP QS-21
By IPP Bureau - December 01, 2022
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Akums partners with Leiutis and Biophore for developing products for multiple therapies
By IPP Bureau - December 01, 2022
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Lonza collaborates with AbTis to extend Bioconjugation capabilities
By IPP Bureau - November 30, 2022
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
.png "Cipla launches Leuprolide Acetate Injection Depot ( (22.5 mg)")
Cipla launches Leuprolide Acetate Injection Depot ( (22.5 mg)
By IPP Bureau - November 30, 2022
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
Briefs: Lupin and GMM Pfaudler
By IPP Bureau - November 30, 2022
The joint venture will help both the parties to further develop the high-margin service business
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
By IPP Bureau - November 30, 2022
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology
By IPP Bureau - November 30, 2022
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
